Charles Schwab Investment Management Inc Cardiff Oncology, Inc. Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 169,974 shares of CRDF stock, worth $579,611. This represents 0.0% of its overall portfolio holdings.
Number of Shares
169,974
Previous 101,664
67.19%
Holding current value
$579,611
Previous $441,000
20.86%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CRDF
# of Institutions
124Shares Held
29MCall Options Held
900KPut Options Held
234K-
Commodore Capital LP New York, NY5.38MShares$18.4 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.12MShares$10.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$8.96 Million0.0% of portfolio
-
Blair William & CO Chicago, IL1.75MShares$5.97 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.45MShares$4.93 Million0.01% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $148M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...